|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Deciphera Pharmaceuticals, Inc. (DCPH) |
|
|
$25.59 0.00 (0.00%) as of 4:30 Mon 6/10
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
60,930,000 |
Market
Cap: |
1.56(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$10.11 - $25.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,687,666 |
Total Buy Value |
$0 |
$0 |
$0 |
$30,291,232 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
0 |
0 |
107,720 |
171,737 |
Total Sell Value |
$0 |
$0 |
$1,495,560 |
$2,560,942 |
Total People Sold |
0 |
0 |
5 |
6 |
Total Sell Transactions |
0 |
0 |
20 |
38 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brightstar Associates Llc |
10% Owner |
|
2024-04-22 |
4 |
OE |
$0.01 |
$481 |
D/D |
48,136 |
23,107,844 |
|
- |
|
Pitman Jama |
SVP, Chief Development Officer |
|
2024-02-16 |
4 |
S |
$15.62 |
$35,405 |
D/D |
(2,267) |
68,031 |
|
-63% |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2024-02-16 |
4 |
S |
$15.62 |
$40,840 |
D/D |
(2,615) |
108,739 |
|
-63% |
|
Martin Daniel C. |
Chief Commercial Officer |
|
2024-02-16 |
4 |
S |
$15.62 |
$35,405 |
D/D |
(2,267) |
55,118 |
|
-63% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2024-02-16 |
4 |
S |
$15.62 |
$47,009 |
D/D |
(3,010) |
80,350 |
|
-63% |
|
Pitman Jama |
SVP, Chief Development Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,725 |
70,298 |
|
- |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,275 |
111,354 |
|
- |
|
Dhanak Dashyant |
EVP & Chief Scientific Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,275 |
158,175 |
|
- |
|
Martin Daniel C. |
Chief Commercial Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,725 |
57,385 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,275 |
83,360 |
|
- |
|
Brightstar Associates Llc |
10% Owner |
|
2024-02-07 |
4 |
OE |
$0.01 |
$9,140 |
D/D |
914,001 |
23,059,708 |
|
- |
|
Pitman Jama |
SVP, Chief Development Officer |
|
2024-01-16 |
4 |
S |
$14.47 |
$23,499 |
D/D |
(1,624) |
50,573 |
|
-76% |
|
Martin Daniel C. |
Chief Commercial Officer |
|
2024-01-16 |
4 |
S |
$14.47 |
$23,499 |
D/D |
(1,624) |
47,660 |
|
-76% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2024-01-16 |
4 |
S |
$14.47 |
$35,234 |
D/D |
(2,435) |
66,085 |
|
-76% |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2024-01-16 |
4 |
S |
$14.47 |
$35,234 |
D/D |
(2,435) |
94,079 |
|
-76% |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2023-12-13 |
4 |
S |
$15.37 |
$42,905 |
D/D |
(2,792) |
96,514 |
|
12% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2023-12-13 |
4 |
S |
$15.37 |
$42,905 |
D/D |
(2,792) |
68,520 |
|
12% |
|
Pitman Jama |
See Remarks |
|
2023-12-13 |
4 |
S |
$15.37 |
$25,540 |
D/D |
(1,662) |
52,197 |
|
12% |
|
Martin Daniel C. |
Chief Commercial Officer |
|
2023-12-13 |
4 |
S |
$15.37 |
$26,539 |
D/D |
(1,727) |
49,284 |
|
12% |
|
Hoerter Steven L. |
President and CEO |
|
2023-12-13 |
4 |
S |
$15.37 |
$471,217 |
D/D |
(30,664) |
72,763 |
|
12% |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2023-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,244 |
99,306 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2023-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,244 |
71,312 |
|
- |
|
Pitman Jama |
See Remarks |
|
2023-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,576 |
53,859 |
|
- |
|
Martin Daniel C. |
Chief Commercial Officer |
|
2023-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,576 |
51,011 |
|
- |
|
Hoerter Steven L. |
President and CEO |
|
2023-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
103,427 |
|
- |
|
290 Records found
|
|
Page 1 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|